/OABI
OABI Stock - OmniAb, Inc.
Healthcare|BiotechnologyNASDAQ
$2.09+3.98%
+$0.08 (+3.98%) • Dec 19
83
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.82
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.85
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+91.4%upside
Target: $4.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for OABI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.07 – $2.11
TARGET (TP)$4.00
STOP LOSS$1.92
RISK/REWARD1:11.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.86
52W High$4.02
52W Low$1.22
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $26.39M | $34.16M | $59.08M | $34.75M | $23.27M |
| Gross Profit | $26.39M | $34.16M | $59.08M | $34.75M | $23.27M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-74,502,000 | $-69,419,000 | $-26,648,000 | $-35,609,000 | $-25,623,000 |
| Net Income | $-62,033,000 | $-50,619,000 | $-22,334,000 | $-27,042,000 | $-17,557,000 |
| Net Margin | -235.1% | -148.2% | -37.8% | -77.8% | -75.5% |
| EPS | $-0.61 | $-0.51 | $-0.26 | $-0.24 | $-0.15 |
Company Overview
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
9
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
9 Bullish0 Neutral/Bearish
Price Targets
$10
Average Target
↑ 357.2% Upside
Now
$6
Low
$10
Average
$13
High
Based on 9 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 29th 2023 | RBC Capital Mkts | Initiation | Outperform | $6 |
| April 21st 2023 | The Benchmark Company | Initiation | Buy | $8 |
| April 13th 2023 | Craig Hallum | Initiation | Buy | $10 |
| February 22nd 2023 | Cowen | Initiation | Outperform | $10 |
| February 13th 2023 | H.C. Wainwright | Initiation | Buy | $11 |
| December 20th 2022 | Truist | Initiation | Buy | $10 |
| December 16th 2022 | Credit Suisse | Initiation | Outperform | $13 |
| November 29th 2022 | SVB Leerink | Initiation | Outperform | $6 |
| November 28th 2022 | Stifel | Initiation | Buy | $12 |
Earnings History & Surprises
OABIBeat Rate
38%
Last 13 quarters
Avg Surprise
+3.1%
EPS vs Estimate
Beats / Misses
5/7
1 met exactly
Latest EPS
$-0.14
Q4 2025
EPS Surprise History
Q1 24
+17.6%
$-0.14vs$-0.17
Q2 24
-11.8%
$-0.19vs$-0.17
Q3 24
+27.8%
$-0.13vs$-0.18
Q4 24
-14.3%
$-0.16vs$-0.14
Q1 25
+7.7%
$-0.12vs$-0.13
Q2 25
0.0%
$-0.17vs$-0.17
Q3 25
-7.1%
$-0.15vs$-0.14
Q4 25
-2.9%
$-0.14vs$-0.14
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 17, 2026 | $-0.08 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.14 | $-0.14 | -2.9% | ✗ MISS |
Q3 2025 | Aug 6, 2025 | $-0.14 | $-0.15 | -7.1% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.17 | $-0.17 | 0.0% | = MET |
Q1 2025 | Mar 18, 2025 | $-0.13 | $-0.12 | +7.7% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.14 | $-0.16 | -14.3% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.18 | $-0.13 | +27.8% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.17 | $-0.19 | -11.8% | ✗ MISS |
Q1 2024 | Mar 20, 2024 | $-0.17 | $-0.14 | +17.6% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.14 | $-0.16 | -14.3% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.11 | $-0.15 | -36.4% | ✗ MISS |
Q2 2023 | May 11, 2023 | $0.05 | $-0.06 | -220.0% | ✗ MISS |
Q1 2023 | Mar 30, 2023 | $0.02 | $0.07 | +250.0% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.04 | $-0.02 | +43.6% | ✓ BEAT |
Q3 2022 | Aug 12, 2022 | — | $-0.09 | — | — |
Q2 2022 | May 20, 2022 | — | $-0.05 | — | — |
Q1 2022 | Mar 28, 2022 | — | $-0.00 | — | — |
Q1 2022 | Mar 25, 2022 | — | $-0.13 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.08 | — | — |
Latest News
OmniAb And Arrowmark Partners Sign A License And Services Agreement For Novel OmniAb-Derived Antibody Discovery Programs With Mabtrx Biosciences; OmniAb To Receive Revenue For Discovery Services As Well As Potential Equity And Royalties
📈 PositiveBenzinga•Nov 17, 2025, 10:28 PM
OmniAb Lowers FY2025 Sales Guidance from $20.000M-$25.000M to $18.000M-$22.000M vs $21.657M Est
📉 NegativeBenzinga•Nov 4, 2025, 09:07 PM
OmniAb Q3 EPS $(0.14), Inline, Sales $2.239M Miss $5.644M Estimate
📉 NegativeBenzinga•Nov 4, 2025, 09:06 PM
OmniAb Files For Offering Of 21.3M Shares By Selling Stockholders
➖ NeutralBenzinga•Sep 12, 2025, 08:05 PM•Also:
OmniAb to raise $30M in private stock placement
➖ NeutralSeeking Alpha•Aug 25, 2025, 11:34 AM
OmniAb Will Sell 21.25M Shares At $1.40 Per Share (Or $1.85 Per Share For Officer And Director Participation), In A Private Placement, Of Approximately $30M
➖ NeutralBenzinga•Aug 25, 2025, 11:05 AM
Frequently Asked Questions about OABI
What is OABI's current stock price?
OmniAb, Inc. (OABI) is currently trading at $2.09 per share. The stock has moved +3.98% today.
What is the analyst price target for OABI?
The average analyst price target for OABI is $4.00, based on 1 analyst.
What sector is OmniAb, Inc. in?
OmniAb, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is OABI's market cap?
OmniAb, Inc. has a market capitalization of $0.22 billion, making it a small-cap company.
Does OABI pay dividends?
No, OmniAb, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARMP
Armata Pharmaceuticals, Inc.
$6.16
Mkt Cap: $0.2B
CCCC
C4 Therapeutics, Inc.
$2.03
Mkt Cap: $0.1B
CDXS
Codexis, Inc.
$1.66
Mkt Cap: $0.1B
IMDX
Insight Molecular Diagnostics Inc.
$5.41
Mkt Cap: $0.2B
IPHA
Innate Pharma S.A.
$1.75
Mkt Cap: $0.1B
IVVD
Invivyd, Inc.
$2.30
Mkt Cap: $0.3B
MIST
Milestone Pharmaceuticals Inc.
$2.15
Mkt Cap: $0.2B
RANI
Rani Therapeutics Holdings, Inc.
$1.51
Mkt Cap: $0.1B
SGMO
Sangamo Therapeutics, Inc.
$0.45
Mkt Cap: $0.2B
TARA
Protara Therapeutics, Inc.
$5.27
Mkt Cap: $0.2B
Explore stocks similar to OABI for comparison